Chromadex Corp expected to post a loss of 8  cents a share - Earnings Preview

Niagen Bioscience

09/08/2022 03:02

* Chromadex Corp  CDXC.OQ   CDXC.O  is expected to show a
rise in
quarterly revenue when it reports  results on August 10. 
    * The Los Angeles California-based  company is expected to
report 
a 5.4% increase in revenue to $18.646 million from $17.7 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Chromadex Corp is
for a
loss of 8 cents per share. For the same quarter last year, the
company reported a loss of 8 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Chromadex
Corp is
$7​, above​ its last closing price of $1.99. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.09       -0.09      -0.11     Missed  -19.6
 Dec. 31 2022  -0.11       -0.10      -0.08     Beat    20
 Sep. 30 2021  -0.09       -0.09      -0.13     Missed  -41.3​
 Jun. 30 2021  -0.08       -0.08      -0.08     Met     2.4
 ​​Mar.        -0.09       -0.09      -0.12     Missed  -39.5
 31 2021                                                
 Dec. 31 2020  -0.10       -0.09      -0.10     Missed  -5.3​
 Sep. 30 2020  -0.11       -0.10      -0.07     Beat    28.6
 Jun. 30 2020  -0.11       -0.10      -0.06     Beat    42.9
 This summary was machine generated August 9 at 02:02 GMT.  All
figures in US dollars  unless otherwise stated